FDA Finds No Link Between GLP-1 Drugs and Thoughts of Suicide
Regulators will continue to evaluate a possible link by reviewing meta-analysis of clinical trials across all GLP-1 products and analyzing postmarketing data in the Sentinel System.
A preliminary FDA review of GLP-1 drugs used to treat patients with type 2 diabetes or obesity finds there is no evidence they cause suicidal thoughts or actions, regulators said in a safety communication. But because the risk cannot be ruled out, regulators will continue to evaluate these drugs.
Regulators have over the last few months reviewed the reports of suicidal thoughts or actions received in the FDA Adverse Event Reporting System (FAERS) related to these drugs. (See below for list of drugs that have evaluated for this risk.) Because the information provided was often limited and because these events can be influenced by other potential factors, regulators said there wasn’t a clear link with the use of GLP-1.
They also reviewed results of clinical trials, including large outcome studies and observational studies and did not find an association between use of GLP-1 and the occurrence of suicidal thoughts or actions.
Regulators will conduct additional evaluations, including of meta-analysis of clinical trials across all GLP-1 products and also analyze postmarketing data in the Sentinel System. Sentinel is a large data network that contains health insurance claims and patient health records.
FDA-Approved GLP-1 Drugs
- Adlyxin (lixisenatide) Type 2 diabetes
- Bydureon BCise (exenatide) Type 2 diabetes
- Byetta (exenatide) Type 2 diabetes
- Mounjaro (tirzepatide) Type 2 diabetes
- Ozempic (semaglutide) Type 2 diabetes
- Rybelsus (semaglutide) Type 2 diabetes
- Saxenda (liraglutide) Obesity/overweight
- Soliqua (lixisenatide + insulin glargine) Type 2 diabetes
- Trulicity (dulaglutide) Type 2 diabetes
- Victoza (liraglutide) Type 2 diabetes
- Wegovy (semaglutide) Obesity/overweight
- Xultophy (liraglutide + insulin degludec) Type 2 diabetes
- Zepbound (tirzepatide) Obesity/overweight
Source: FDA
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
